Asahi Kasei Expands Global Pharma Presence with Calliditas Acquisition

Asahi Kasei (JP:3407) has released an update.

Asahi Kasei Corporation successfully completed its tender offer for shares of Calliditas Therapeutics AB, with the acquisition resulting in Calliditas becoming a wholly-owned subsidiary. This strategic move is expected to strengthen Asahi Kasei’s presence in the U.S. and European pharmaceutical markets, particularly in the renal and autoimmune disease sectors, and presents new in-licensing opportunities as a global pharma company. The tender offer, which was well received, resulted in Asahi Kasei purchasing approximately 93.30% of Calliditas outstanding shares, costing around SEK 10.5 billion.

For further insights into JP:3407 stock, check out TipRanks’ Stock Analysis page.